Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 07, 2025

BUY
$4.83 - $10.57 $1.05 Million - $2.29 Million
216,907 Added 31.66%
902,076 $8.86 Billion
Q1 2025

May 06, 2025

BUY
$6.18 - $11.66 $4.23 Million - $7.99 Million
685,169 New
685,169 $4.98 Billion

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $690M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Readystate Asset Management LP Portfolio

Follow Readystate Asset Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Readystate Asset Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Readystate Asset Management LP with notifications on news.